• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

BioVex

edit

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease.

Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

Recent Milestones

edit

• 
  BioVex was acquired by Amgen for $1B. (1/25/11)
  Posted 1/25/11 at 9:51pm via masshightech.com
• 
  BioVex — Amgen, has reached agreement to acquire BioVex Group Inc. for what could total $1 billion (1/25/11)
  Posted 1/25/11 at 7:34am via masshightech.com
• 
  BioVex — has launched a Phase 3 study of its OncoVEXGM-CSF as a treatment for patients with locally advanced squamous cell carcinoma of the head and neck. (12/10/10)
  Posted 12/13/10 at 4:54am via masshightech.com
• 
  BioVex received $30M in Series F funding. (11/10/09)
  Posted 11/10/09 at 3:39pm via xconomy.com
• 
  BioVex received $40M in Series F funding. (3/30/09)
  Posted 3/30/09 at 2:17pm via fiercebiotech.com
• 
  BioVex received $34.8M (£17M) in Series A funding. (11/15/07)
  Posted 3/13/09 at 5:55am via redorbit.com
• 
  BioVex added Philip Astley-Sparke as President, Chief Executive Officer and Director.
  Posted 3/13/09 at 5:55am
• 
  BioVex added Dr Robert Coffin as Chief Technology Officer, Founder and Director.
  Posted 3/13/09 at 5:55am
• 
  BioVex added Stephen Gorgol as Chief Financial Officer , Treasurer and Secretary.
  Posted 3/13/09 at 5:55am
• 
  BioVex added Dr Colin Love as SVP Product Development.
  Posted 3/13/09 at 5:55am
• 
  BioVex added Howard Goldsweig as MD, Chief Medical Officer.
  Posted 3/13/09 at 5:55am
• 
  BioVex added Lance Weed as VP Operations.
  Posted 3/13/09 at 5:55am

Videos

Screenshots

edit

Above: Home Page
Uploaded: 1/29/10

Traffic Analytics

Compete

Sources

1. BioVex to be acquired by Amgen for up to $1 billion (masshightech.com) [edit]
2. BioVex Raises $22 Million in First Close of Series E Financing (redorbit.com) [edit]
3. BioVex Raises $40 Million (fiercebiotech.com) [edit]
4. Xconomy Boston (xconomy.com) [edit]
BioVex launches Phase 3 study on head and neck cancer treatment (masshightech.com) [edit]
BioVex to be acquired by Amgen for up to $1 billion (masshightech.com) [edit]